WVEHIGH SIGNALFINANCIAL10-K

WVE substantially strengthened its cash position while operating losses roughly doubled and the company refined its strategic focus around three lead hepatic/metabolic RNA medicine programs.

The dramatic improvement in cash position (nearly doubling to $602M) provides significant runway for operations, likely from equity financing or partnership proceeds. However, operating losses roughly doubled while R&D spending increased modestly, suggesting either one-time charges or declining operational efficiency that warrants investor scrutiny.

Comparing 2026-02-26 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

WVE's balance sheet strengthened dramatically with cash nearly doubling to $602M and total assets growing substantially, while liabilities decreased modestly. Operating performance deteriorated significantly with losses roughly doubling despite only moderate R&D expense increases, and operating cash burn increased to $187.5M. The enhanced cash position provides substantial operational runway, but the widening losses relative to spending growth raises questions about cost management and operational efficiency.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+99.3%
$302.1M→$602.1M

Cash position surged 99.3% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
-95.1%
-$110.4M→-$215.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Assets
Balance Sheet
+91.9%
$320.4M→$614.8M

Current assets grew 91.9% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+81.3%
$352.2M→$638.5M

Asset base grew 81.3% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
-24.1%
-$151.0M→-$187.5M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Capital Expenditure
Cash Flow
-23.5%
$938K→$718K

Capex reduced 23.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
-16.7%
$134.8M→$112.3M

Liabilities reduced 16.7% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
+14.5%
$159.7M→$182.8M

R&D investment increased 14.5% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
-14.3%
$111.0M→$95.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Accounts Receivable
Balance Sheet
-10.3%
$1.4M→$1.3M

Receivables declined — improved collection efficiency or conservative revenue recognition.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-04
ADDED
The number of outstanding ordinary shares of the registrant as of February 19, 2026 was 188,254,954 .
Our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our pipeline is focused on our obesity (WVE-007), alpha-1 antitrypsin deficiency ( AATD ) (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs for Duchenne muscular dystrophy ( DMD ) and Huntington s disease ( HD ), as well as several preclinical programs utilizing our versatile RNA medicines platform.
We are actively advancing programs across modalities, including RNA interference ( RNAi ) (silencing), RNA editing, which uses novel A-to-I RNA editing oligonucleotides ( AIMers ), antisense silencing, and splicing.
We have also advanced novel bifunctional modalities designed to silence multiple targets or silence one target while simultaneously editing or upregulating another unique target.
+7 more — sign up free →
REMOVED
The number of outstanding ordinary shares of the registrant as of February 24, 2025 was 153,486,021 .
Our toolkit of RNA-targeting modalities includes RNA editing, splicing, silencing using RNA interference ( siRNA") and antisense silencing, providing us with unique capabilities for designing and sustainably delivering candidates that optimally address disease biology.
Our diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency ( AATD ), Duchenne muscular dystrophy ( DMD ), and Huntington s disease ( HD ), as well as several preclinical programs utilizing our versatile RNA medicines platform.
We are actively advancing programs using four distinct modalities, including novel A-to-I RNA editing oligonucleotides ( AIMers ).
These modalities include: RNA editing, which uses AIMers that are designed to target single bases on an RNA transcript and recruit endogenous ADAR enzymes that naturally possess the ability to change an adenine (A) to an inosine (I), which cells read as guanine (G).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →